Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04730999
Title Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico Italiano di Ricerca Clinica

lung small cell carcinoma

pulmonary neuroendocrine tumor


Atezolizumab + Bevacizumab + Carboplatin + Etoposide

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.